Actelion reports earnings

Actelion (SWX:ATLN) reported first quarter EPS of CHF1.82, up 52% from EPS of CHF1.20 for the same period last year. First quarter revenues were up 45% to CHF146.4 million ($122.5 million) from CHF101.1 million in the first quarter of 2004.

Revenues were driven by continued growth of Tracleer bosentan to treat pulmonary arterial hypertension (PAH). The drug posted CHF139.8 million ($117 million) in first quarter sales, up 44% from CHF97.1 million for the same period last year. ...